Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen

Actuate Therapeutics (NASDAQ:ACTU) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Actuate Therapeutics in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Actuate Therapeutics Stock Up 2.1%

Shares of ACTU stock opened at $4.33 on Friday. The firm has a market cap of $100.63 million, a price-to-earnings ratio of -4.98 and a beta of -0.16. Actuate Therapeutics has a 52-week low of $4.04 and a 52-week high of $11.99. The company’s 50 day moving average is $5.85 and its 200 day moving average is $6.76.

Actuate Therapeutics (NASDAQ:ACTU) last posted its earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02.

Insider Activity

In related news, Director Todd S. Thomson sold 280,000 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $5.80, for a total value of $1,624,000.00. Following the completion of the transaction, the director directly owned 904,795 shares of the company’s stock, valued at $5,247,811. This trade represents a 23.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 69.34% of the stock is currently owned by company insiders.

Institutional Trading of Actuate Therapeutics

Several large investors have recently bought and sold shares of ACTU. ABS Direct Equity Fund LLC purchased a new position in shares of Actuate Therapeutics in the fourth quarter worth $40,000. Deutsche Bank AG raised its stake in Actuate Therapeutics by 640.0% in the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after acquiring an additional 8,051 shares during the last quarter. Sfmg LLC lifted its position in Actuate Therapeutics by 32.3% during the 2nd quarter. Sfmg LLC now owns 14,550 shares of the company’s stock worth $89,000 after acquiring an additional 3,550 shares during the period. Bank of America Corp DE grew its stake in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Actuate Therapeutics in the fourth quarter valued at about $102,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.